Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis. [PDF]
, 2020 BACKGROUND Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. This drug can enhance the inactivated state of voltage-gated sodium channels, preferentially inhibiting the persistent component of the sodium ...
Silvestrini, Mauro +6 more
core +4 more sources
Long-term Impact of Cenobamate on Cognition in Patients with Drug-Resistant Focal Epilepsy: Outcomes from an Exploratory Real-World Study [PDF]
Neurology and TherapyIntroduction Cognitive adverse events are a common issue in patients receiving later-generation antiseizure medications (ASMs). In this study, we assessed the long-term effects of cenobamate on cognitive endpoints in patients with drug-resistant focal ...
Teresa Ramirez-Garcia +6 more
doaj +2 more sources
Effectiveness of adjunctive low‐dose clobazam in adults with focal drug‐resistant epilepsy and incomplete response to cenobamate: A real‐world study [PDF]
Epilepsia OpenObjective Cenobamate (CNB) is a highly effective antiseizure medication (ASM) for focal drug‐resistant epilepsy (DRE); nevertheless, even with CNB treatment and optimized therapy, a substantial proportion of patients continued to experience seizures ...
Ilaria Ciullo +8 more
doaj +2 more sources
Cenobamate for treatment-resistant focal seizures: current evidence and place in therapy
Journal of Central Nervous System Disease, 2022 Background Cenobamate is newly approved for partial-onset seizures in adults, albeit the mechanism of its action remain poorly understood. Methods This article aims to review the efficacy, safety, and tolerability of cenobamate in treating partial-onset
Alok Singh
doaj +1 more source
Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program [PDF]
, 2021 Objective: We determined retention on open-label cenobamate therapy in the clinical development program to assess the long-term efficacy and tolerability of adjunctive cenobamate in individuals with uncontrolled focal seizures.
Sander, JW +5 more
core +1 more source
An Ex Vivo Evaluation of Cenobamate Administered via Enteral Tubes
Drugs in R&D, 2020 Background Cenobamate is a new, Food and Drug Administration (FDA)-approved oral antiepileptic drug for treatment of focal seizures in adults. This study examined recovery of cenobamate from suspensions administered through ex vivo enteral feeding tubes.
Louis Ferrari +3 more
doaj +1 more source
, 2022 Uncontrolled epilepsy has persisted despite development of numerous antiseizure medications (ASMs) over the past 25 years, and more effective treatments are needed.
James W. Wheless (6034235)
core +1 more source
Clinical and Translational Science, 2022 Cenobamate (XCOPRI and ONTOZRY) is a novel antiseizure medication for the treatment of focal‐onset seizures. Nonetheless, there is limited information on the pharmacokinetics (PKs), safety, and efficacy of cenobamate in Asian people, including Japanese ...
Eunsol Yang +6 more
doaj +1 more source
Cenobamate is an effective treatment for drug resistance focal epilepsy: a critical review
MGM Journal of Medical Sciences, 2023 Cenobamate, recently approved anticonvulsant by the Food and Drug Administration (FDA), stands as a potential remedy for drug-resistant epilepsy (DRE). It shows promise in enhancing seizure management efficacy.
Jayasheela S Hiremath +2 more
doaj +1 more source
Journal of Education, Health and Sport, 2022 Epilepsy is one of the most common diseases of the nervous system, characterized by the occurrence of recurrent and unprovoked seizures, which are an expression of abnormal brain activity associated with sudden and excessive bioelectric discharges ...
Zofia Pietrzak +5 more
doaj +1 more source